Abstract: Rhenium-188 is a useful radionuclide for targeted therapy thanks to the high energy (2.12 MeV) Re-based radiopharmaceuticals.
INTRODUCTION
Rhenium belongs to the group 7 of the periodic table, same as that of 99m Tc, the workhorse of nuclear medicine. Rhenium has two important radioisotopes, 186 Re [half-life -3.71 days, E βmax -1.09 MeV, E γ -136 keV (9%)] and 2. DISCUSSION 2.1. Nanosorbents for 188 W/ 188 Re Generator Preparation 188 W/ 188 Re generator is an excellent source for availing no-carrier-added (NCA) grade 188 Re. Most of the separation methodologies which have been reported for 99 Mo/ 99m Tc generators have also been exploited for preparation of 188 W/ 188 Re generators [2] . Out of these procedures, the alumina based column chromatographic approach wherein 188 W is absorbed on bulk alumina matrix and 188 Re is selectively eluted using saline solution at regular intervals, has been identified as the most reliable method for the preparation of 188 W/ 188 Re generator. Owing to the limited sorption capacity of bulk alumina (~50 mg W/g), clinical-scale 188 W/ 188 Re generator can only be prepared using high specific activity (150-190 GBq/g) 188 W that can be produced in only very few high flux (~10 15 n.cm -2 .s -1 ) reactors available (High Flux Isotope Reactor at Oak Ridge National Laboratory in United States and SM Reactor at Dimitrograd in Russia) in the world. Even while using high specific activity 188 W produced in these reactors, the 188 W/ 188 Re generators currently available yield low specific volume (activity/ mL) of 188 Re and require post-elution concentration procedures prior to radiopharmaceutical preparation, which is not always very convenient to perform in hospital radiopharmacies [3] . From this perspective, it is desirable to develop a 188 W/ 188 Re generator where the concentration step can be avoided to simplify the operational procedure for widespread clinical utility.
Use of nanomaterials as adsorbents for 188 W/ 188 Re generator holds promise as they take advantage of the unique physiochemical properties realized at nanoscale that cannot be anticipated from bulk counterparts of the same chemical composition. The defining feature of a nanomaterial is that its properties depend not only on composition but also on its size and shape. One of the specific properties of this class of material is that a high percent of the atoms lies on the surface and the material possesses high surface area. These surface atoms are unsaturated and possess high chemical activity. Therefore, such materials demonstrate high sorption capacity and enhanced selectivity for 188 W resulting in elution of 188 Re with adequate radioactive concentration and high radionuclidic purity. The above properties make nanomaterials an exciting platform to develop into the realm of 188 W/ 188 Re generator technology with properties that are difficult to achieve using bulk materials.
The ability of three nanomaterial based sorbents (nanocrystalline titania (TiP), zirconia (ZrO 2 ) and alumina (γ-Al 2 O 3 )) have been comprehensively studied and profusely explored for the development of 188 W/ 188 Re generators by our group [4] [5] [6] [7] . Taking advantage of the new physical properties uniquely associated with nanomaterials, 188 W/ 188 Re generators were prepared using 188 W having specific activity of 3-5 Ci/g. A scrutiny of the results depicted in Table 1 reveals that all these sorbents are suitable for preparation of 188 W/ 188 Re generators. Though testing of these nanomaterials was done by using lower load of 188 W, the capacity of the generator can easily be scaled up to >37 GBq (1 Ci) activity levels as the capacity of the nanomatarials are very high. Among all the sorbents used, γ-Al 2 O 3 was found to exhibit the highest sorption capacity under dynamic conditions as compared to TiP and ZrO 2 and is therefore the most appropriate sorbent for the preparation of clinical-scale 188 W/ 188 Re generator. The performance of these generators was studied for more than 6 months and reported to be satisfactory. Not only were the 188 Re elution yields appreciably high but also the level of radionuclidic, radiochemical and chemical impurities in the 188 Re obtained from all these generators were well within the acceptable limits prescribed in the pharmacopoeias [8] .
The mechanism of uptake of 188 W and elution of 188 Re from the nanosorbent based chromatographic columns could be explained on the basis of pH dependent surface charge on nanosorbents. There are various anionic species of tungsten depending on the pH of the medium. At pH 6, the predominant species is W 12 188 Re generators prepared using nanomaterial based sorbents is comparable with conventional alumina based generators in terms of 188 Re elution yield and the purity of the eluate. However, due to higher sorption capacity of nanomaterials, relatively lower specific activity 188 Re generators. Also if the existing generator manufacturers can shift to γ-Al 2 O 3 as adsorbent, the generator capacity can be increased. Simultaneously the activity per mL can also be increased by using smaller bed size for the column and lower volume of eluent.
2.2.

188
Re Based Radiopharmaceuticals
The Radiopharmaceuticals Division of the Bhabha Atomic Research Centre has been carrying out research on the development of 188 Re radiopharmaceuticals for over 25 years. The following sections give details of some of the important developments.
2.3.
188
Re(V)DMSA (DMSA -Dimercapto Succinic Acid) 99m Tc(V)DMSA is a widely used radiopharmaceutical for diagnostic imaging of medullary carcinoma of thyroid [9] [10] [11] , head and neck tumors, [12, 13] , soft tissue tumors and metastatic bone lesions and osseous metastasis from breast cancer [14] [15] [16] . Rhenium being the therapeutic analogue of 99m Tc, which shares similar chemistry, envisaging use of 186/188 Re(V)DMSA for therapeutic applications is obvious. Bisunadan et al. reported the first study on the preparation and use of 186 Re(V)DMSA for tumor therapy [17] . Subsequently, several others reported the preparation and use of 186/188 Re(V)DMSA for different cancers [18] [19] [20] . General approach for the preparation of 186 reported the preparation of 186 Re(V)DMSA and its biological evaluation in Wistar rats [21] . They observed significant uptake of the radiotracer in kidneys, which limited wide spread application of this therapeutic agent in the clinic. Attempts to reduce the kidney uptake of 186/188 Re(V)DMSA using blocking agents were not successful [22] . Later, Kothari et al. found that signifycant reduction in kidney uptake of 186/188 Re(V)DMSA could be achieved by modifying the method of preparation of the radiotracer. The 186/188 Re(V)DMSA prepared using sodium metabisulphite (Na 2 S 2 O 5 ) as reducing agent in place of stannous chloride (SnCl 2 ), showed significant reduction in kidney uptake (only 0.68±0.06 %ID/g at 24 h post injection (p.i.)). It is pertinent to note that kidney uptake observed with 186/188 Re(V)DMSA prepared by conventional method, using stannous chloride as reducing agent, was 2.93±0.93 %ID/g at the same time point [23] . Though the reason for this observation was not understood, authors observed a noticeable change in the isomeric ratio of the 186/188 Re(V)DMSA complex. The highperformance liquid chromatography (HPLC) analysis of 186/188 Re(V)DMSA prepared by conventional method using stannous chloride as reducing agent showed three major peaks representing anti, syn-endo and syn- 
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Consistent performance for 6 months exo isomers, respectively, as shown in Figure 1 (A) [24] . Apart from these major peaks, a minor peak representing an unknown structure was observed between the anti and syn-endo isomeric forms. Kothari et al. observed significant contribution from this peak in 186/188 Re(V)DMSA prepared using sodium metabisulphite reducing agent [ Figure 1(B) ] [23] . However, it is not clear whether it has any correlation with reduction in kidney uptake and the phenomenon is worth investigating.
Recently, our group developed a lyophilized kit for the preparation of 188 Re(V)DMSA at room temperature [unpublished results]. It is known that presence of oxalate facilitate reduction of rhenium, therefore the room temperature kit (RT kit) contained sodium oxalate in addition to other ingredients of conventional kit, i.e. DMSA and stannous chloride. Using this kit 188 Re(V)DMSA could be prepared in >98% yield at room temperature in 15 min. Though HPLC analysis of 188 Re(V)DMSA prepared using RT kit showed similar isomeric peak patterns, the isomeric ratios were different. The 188 Re(V)DMSA prepared following the conventional method, by heating at 100°C for 30 min, had the anti, syn-endo and syn-exo isomers in the ratio 48:39:13, whereas, the 188 Re(V)DMSA prepared using RT kit at room temperature had the isomeric ratios 48:29:23, respectively. It is interesting to note that experimental conditions had effect only on the synendo and syn-exo isomeric ratio and percentage contribution from the anti isomer remained same. This apparently small change in the isomeric ratio of 188 Re(V)DMSA prepared using RT kit, however, had profound influence on the overall biodistribution pattern in Swiss mice bearing fibrosarcoma tumor. With 188 Re(V)DMSA prepared following conventional method, we observed uptake in bone (15 %ID/g), kidney (3.2 %ID/g) and tumor (2.2 %ID/g) at 60 min p.i. Subsequently, the activity cleared from all organs and at 24 h p.i., the activity in bone, kidney and tumor were 2.8 %ID/g, 1.5 %ID/g and 0.2 %ID/g, respectively.
Similarly, biodistribution of 188 Re(V)DMSA prepared using RT kit showed initial uptake of 6 %ID/g, 1.8 %ID/g and 1.4 %ID/g in bone, kidney and tumor, respectively, at 60 min p.i. It could be noted that uptake values in these organs/tissue are relatively lower compared to the distribution of 188 Re(V)DMSA prepared by conventional method at the same time point. However, at 24 h p.i. a significant increase in bone uptake (22 %ID/g) was observed, while the uptake values in kidney (1.2 %ID/g) and tumor (0.4 %ID/g) were similar to that of 188 Re(V)DMSA prepared by conventional method.
In another experiment, 188 Re(V)DMSA prepared using RT kit was heated at 100°C for 10 min. Subsequent HPLC analysis of the sample revealed that isomeric ratios changed from 48:29:23 to 48:38:14, which was very close to that of 188 Re(V)DMSA prepared using conventional kit. This experiment possibly indicated higher thermodynamic stability of syn-endo isomer vis-à-vis syn-exo isomer. Proceeding further, we carried out biodistribution of 188 Re(V)DMSA prepared by RT kit at room temperature and then heating it again at 100°C for 10 min. As expected, the biodistribution results were similar to the one obtained with 188 Re(V)DMSA prepared by conventional method. These results indicate that higher bone uptake observed in the case of 188 Re(V)DMSA prepared using RT kit at room temperature may be due to the syn-exo isomer. This interesting results advocate further investigation to understand the distribution of individual isomers. If an isomer was found to be suitable for a particular application, modification of reaction conditions to maximize the yield of that isomer could be the next logical step forward.
2.4.
186/188
Re-HEDP (HEDP -Hydroxyethane 1,1-Diphosphonic Acid) 186/188 Re-HEDP is a clinically established palliating agent for bone pain due to osseous metastasis [25] [26] [27] [28] [29] [30] [31] . Initial HEDP studies were carried out using 186 Re radioisotope. Rhenium-186 is a reactor produced radioisotope from neutron radiative capture (n,γ) reaction on enriched 185 Re or natural rhenium (37.4% enriched in 185 Re).
Kothari et al. reported preparation and evaluated 186 Re-HEDP from 186 Re produced from natural rhenium [32] . This was probably the first study, which used 186 Re produced from natural rhenium in a medium flux (6 x 10 13 neutrons/cm 2 /s) reactor. The 186 Re-HEDP prepared under optimized conditions (pH -2, SnCl 2 .2H 2 O -10 mg, HEDP -50 mg, reaction temperature -100ºC, time -30 min) was evaluated in normal Wistar rats. The distribution study showed significant uptake of 186 Re-HEDP in bone (30.7 ± 0.04 %ID/organ at 3 h p.i.) and retention thereafter, throughout the duration of the study (29.5 ± 4.0 %ID/organ at 48 h p.i.). There was no significant uptake of activity in any other major organs. During optimization studies, authors observed that >98% radiochemical purity could be achieved with HEDP amount as low as 1.25 mg/mL, stannous chloride 0.4 mg and total rhenium content 100 µg, rest of the reaction conditions remaining the same. However, to achieve stability of 186 Re-HEDP for extended periods, significantly higher amounts of the reactants were necessary. This observation was in agreement with a study reported by Elder et al., which established the influence of amounts of HEDP, stannous chloride and the total rhenium content on the final structure of Re-HEDP, and consequently, its biodistribution [33] . Use of natural rhenium resulted in, unavoidable, co-production of 188 Re (Half-life -16.9 h). Therefore, the authors cooled the irradiated sample for four days to reduce the activity of 188 Re to ~6% of the total activity. Authors noticed, and highlighted, the practical difficulty with this approach of 186 Re-HEDP preparation, since it resulted in significant reduction in 186 Re-activity during the cooling period. By this approach, preparation of clinical dose of 186 Re-HEDP was virtually impractical. As an alternative, authors proposed mixed radionuclide therapy with 186/188 Re-HEDP, which could eliminate the 4 day cooling requirement. However, dosimetry of mixed radionuclide therapy approach with 186 188 Re-HEDP [35] . Preparation of 188 Re-HEDP requires addition of carrier rhenium to carrier-free Na 188 ReO 4 from 188 W/ 188 Re generator. This is essential to obtain the 188 Re-HEDP species which shows the pharmacokinetics necessary for a bone pain palliating agent. Along with HEDP (10 mg), gentisic acid (3 mg) and stannous chloride dihydrate (3.7 mg), Verdera et al., included carrier potassium perrhenate (300 µg, ~1 µmol) in their lyophilized HEDP kit. Though the authors have not mentioned the shelf-life of such lyophilized HEDP kits, presence of stannous and carrier perrhenate together in the kit could significantly shorten the shelf-life of the kit.
Mallia et al. circumvented this problem of short shelf-life of the kit by excluding the carrier perrhenate from the HEDP kits [36] . While rest of the kit components and their amounts remained similar to that of the kit reported by Verdera et al., preparation of 188 Re-HEDP using this kit required addition of 1µmol of carrier perrhenate along with freshly eluted Na 188 ReO 4 from 188 W/ 188 Re generator. Subsequently, heating the kit vial at 100°C for 20 min resulted in the formation of 188 Re-HEDP in more than 98% radiochemical purity. After adjusting the pH of the preparation to physiological conditions (using sterile sodium acetate provided with the kit), the preparation is ready for patient administration. Shelf-life of this kit was one year from the date of production. Clinical evaluation of 188 Re-HEDP prepared using these kits are being carried out in different nuclear medicine centres in India. The development of lyophilized HEDP kit in BARC is well-timed considering the increasing number of nuclear medicine centres in India offering 188 Retherapy.
2.5.
188
ReN-DEDC/Lipiodol (DEDC -Diethyl Dithiocarbamate)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and represents the second most common causes of cancer death worldwide [37] . Patients presented with late stage HCC, which are unresectable, are recommended for loco-regional therapies such as transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT) or sorafinib therapy, depending on the stage of the disease [38] . SIRT is also called TARE or transarterial radioembolization. TARE is similar to TACE, the only difference being the use of radiation emitted from radioisotopes for therapy in former, while the latter uses chemotherapeutics. TARE using radiolabelled particles and colloids are one of the options for inoperable HCC patients. 188 Relabeled lipiodol for TARE [39] . Their approach involved preparation of 188 Re-EDTB (EDTB -N,N,N",N"-tetrakis(2-benzymidazolylmethyl)-l,2-ethanediamine) and subsequent incubation with EDTB-lipiodol at 70ºC for 2h. This procedure resulted in 188 Re-lipiodol >98% yield. Biodistribution studies carried out in Sprague Dawley rats showed slow clearance of activity from liver, however, accumulation of significant levels of activity in lungs and kidneys severely limited its clinical applications.
Jeong et al. reported preparation and use of a lipiodol solution of 188 Re-TDD (TDD -2,2,9,9-Tetramethyl-4,7-diaza-1,10-decanedithiol) for therapy of liver cancer [40] . This method involved preparation of a lipophilic complex, 188 Re-TDD, and subsequent extraction into lipiodol. Due to the lipophilic nature of the 188 Re-TDD complex, it is retained in lipiodol phase. This radioactive lipiodol solution was used for TARE procedure. Though 188 Re-TDD could be prepared in good yields and extracted into lipiodol, authors noticed that its retention in liver is not good enough to treat liver cancer patients. The same group subsequently reported a modified form of 188 Re-TDD, 188 Re-HDD (HDD -4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol), which showed higher retention in liver. Kumar et al. reported an IAEA-sponsored clinical study, which concluded that TARE with 188 Re-HDD is safe and effective option for the therapy of inoperable hepatocellular carcinoma [41] . Lyophilized kits for the preparation of 188 Re-HDD are available commercially.
Although, 188 Re-HDD complex could be prepared in high yields with commercially available kits, extraction of the complex into the lipiodol phase was not satisfactory. Boschi et al. reported preparation of a lipiodol solution of 188 ReN-DEDC (DEDC -diethyl dithiocarbamate) complex [42] . This approach was very similar to that of Jae Min Jeong et al. wherein a lipophilic 188 Re-complex was prepared and extracted into lipiodol. The complex 188 ReN-DEDC is prepared in two steps. First step involved preparation of 188 Renitrido core, which was subsequently used for radiolabeling DEDC ligand to obtain 188 ReN-DEDC complex. By this method, 188 ReN-DEDC complex could be prepared in >97% radiochemical purity and >96% extraction of the complex into lipiodol could be achieved. Clinical trials with 188 ReN-DEDC/lipiodol showed retention of activity in liver with no activity accumulation seen in lungs, kidneys or any other vital organs.
Considering increasing number of liver cancer incidences in India, a need for locally available, effective and economical TARE agent was felt. Following the procedure reported by Prof. Duatti's group, we developed a two-vial kit for the preparation of 188 ReN-DEDC. First kit vial used for the preparation of 188 ReN core, contained 2 mg of DTCz (N-methyl-Smethyl-dithiocarbazate), 28 mg of sodium oxalate and 0.8 mg of stannous chloride dihydrate. The second kit contained 27 mg of DEDC and carbonate buffer (1 M). The procedure involved addition of up to 3 mL of freshly eluted Na 188 ReO 4 containing 150 µL of glacial acetic acid to the kit vial 1. Upon incubating at room temperature for 30 min, 188 ReN core could be prepared in >90% yield. In the second step, kit vial 2 was reconstituted with 2 mL of sterile saline and 1.5 mL of the solution is aseptically transferred to kit vial 1. International Journal of Nuclear Medicine Research, 2017 73 Subsequently, kit vial 1 was heated at 70ºC for 20 min to obtain 188 ReN-DEDC complex. Analysis of the reaction mixture showed that 188 ReN-DEDC complex was formed in >80% purity. In the third step, 1-2 mL of sterile lipiodol was added to kit vial 1, the contents were thoroughly mixed for 5 min and subsequently centrifuged for 10 min to effect separation of the two layers. The lipiodol layer containing the 188 ReN-DEDC complex was carefully separated and used for TARE. The SPECT/CT images obtained during preliminary clinical trials using 188 ReN-DEDC/lipiodol, carried out in Tata Memorial Hospital, Mumbai, showed retention of the 188 Re-activity in liver 24 h p.i., with no detectable accumulation of activity in lungs or kidneys. A regulatory clearance to manufacture and supply the kits in India is underway.
2.6.
188
Re-Agents for Radiation Synovectomy
Radiation synovectomy is an effective treatment for rheumatoid arthritis [43] [44] [45] [46] . This modality, which is an alternative to surgical intervention, involves intraarticular injection of beta emitting radiopharmaceutical to control the synovial inflammation. A critical requirement of radiation synovectomy agents is their ability to localize at the point of injection, since leaching of the agent will render the therapy ineffective. A general approach to minimize the effect of leaching is to use a short-lived radioisotope such that therapeutic dose can be delivered at the point of inflammation in a short span of time. Another approach to minimize leaching is to use radiolabeled particles with larger size [47] .
Yttrium-90 and 32 P are two radioisotopes commonly used for the preparation of synovectomy agents [48, 49] . Both radioisotopes have high-energy beta emissions suitable for synovectomy applications. However, being pure beta emitters, both radioisotopes exclude the possibility of imaging to assess localization of the injected radiopharmaceutical. Additionally, the 14 day half-life of 32 P is too long and in the event of leaching it may result in radiation dose to other organs/tissues. In this context, 188 Re has significant advantages over both 90 Y and 32 P, owing to its favorable physical and chemicals properties described in section 1. Additionally, it has relatively short half-life (16.9 hours) and it is a generator produced radioisotope. Preparation and evaluation of 188 Re labeled microspheres and 188 Re-suphur colloids was reported earlier [50] [51] [52] [53] . However, significant leaching from the site of injection severely limited their application. Hydroxyl apatite (HA), a major component of the bone matrix, had been radiolabeled with 186/188 Re for synovectomy applications [54, 55] . However, these agents exhibited poor in vitro stability, which limited their application.
Kothari et al. reported direct labeling of HA with 188 Re [47] . Their method involved incubation of freshly eluted Na 188 ReO 4 with HA (10 mg), sodium oxalate (10 mg) and stannous chloride (10 mg) at room temperature for 1 hour. The pH of the solution was maintained at 1.4 using hydrochloric acid. Subsequently, the 188 Re-HA particles were washed with ascorbic acid to remove free perrhenate and resuspended in ascorbic acid medium. By this method, 188 Re-HA particles could be prepared in >98% yield. Authors observed that presence of oxalate significantly reduced the dissolution of HA under acidic conditions. Particle size of cold Re-HA, determined by laser diffraction, was found to be between 2-20 µm (>90%). 188 Re-HA particles were found to be stable in ascorbic acid medium for up to 4 days. Upon intraarticular injection of 188 Re-HA particles in rat joints, extraarticular leakage of only 2.5% was observed even after 2 days post injection. Overall, this study demonstrated the potential of 188 Re-HA particles for therapy of inflamed synovial joints.
Miscellaneous 188
Re-Radiopharmaceuticals 2.7.1. 188 
Re-Skin Patches
Application of radioactive skin patches is an effective mode of therapy for skin cancers and superficial tumors [56] . This modality is an alternative to teletherapy, brachytherapy or kilo voltage x-ray therapy for the treatment of superficial cancers. Papers or skin patches incorporating beta emitting radionuclides such as 188 
Re or 166
Ho has been reported earlier [57] [58] [59] .
Mukharjee et al. reported a modified procedure for the preparation of 188 Re-bandage patch [60] . Their method involved preparation of 188 Re-tin colloid followed by trapping of the radioactive colloidal particle on to a 0.22 µm Millipore filter by passing the solution through the filter. The filter paper was subsequently sandwiched between two nitrocellulose membranes and then placed on an adhesive bandage for therapeutic applications. Radioactive bandages thus prepared were evaluated in melanoma tumor bearing C57BL/6 mice. The study conclusively demonstrated the efficacy and potential of 188 Re-bandages for the therapy of superficial tumors [ Figure 2 ]. 
188 Re-EC (EC-Ethylene Dicystene) for Endovascular Therapy
Restenosis is an event with significant probability following coronary angioplasty [61, 62] . One of the procedures followed to avoid/minimize restenosis of dilated artery by balloon angioplasty is by local delivery of radiation dose to the dilated arteries [63] [64] [65] . Dose delivery is generally achieved using balloon filled with radioactive solution by a procedure similar to balloon angioplasty. One of the inherent risks in this procedure is the rupture of balloon during the procedure leading to leakage of the radioactive liquid into circulation. Therefore, the pharmacokinetics of the radiotracer should be such that in the event of a balloon rupture, the activity should clear from the body within a short period of time, such that dose burden on the patient could be minimized. A comparison between Na 188 ReO 4 , 188 Re-MAG 3 and 188 Re-DTPA for this application revealed that 188 Re-MAG 3 is most suitable for the purpose [64] . However, the long-term stability of 188 Re-MAG 3 is doubtful [66] .
Das et al. [67] reported the preparation of 186/188 Re-EC, an analogue of 99m Tc-EC, which is a clinically used renal agent, as a substitute for 188 Re-MAG 3 . Optimized procedure for the preparation of 186/188 Re-EC involved incubation of a mixture of 10 mM solution of EC with stannous chloride (2 mg) and Na 186/188 ReO 4 at 100ºC for 20 min. The pH of the reaction mixture was maintained at 2. By this method, 188 Re-EC could be prepared in >98% radiochemical purity. Biodistribution studies of 186/188 Re-EC carried out in Wistar rats indicated that in terms of clearance and dose delivered to other vital organs, 186/188 Re-EC had distinct advantages over other rhenium agents used for endovascular brachy therapy applications. In addition, 186/188 Re-EC was also found to retain its radiochemical purity for a longer time compared to 188 Re-MAG 3 .
2.7.3. Phosphonates have shown good affinity for bone matrix and they have been utilized to deliver therapeutic dose of radiation to pain causing metastatic or primary bone lesions to obtain palliative effect to the patients. A number of phosphonates radiolabeled with beta emitting radionuclides such as 186 Re, 188 Re, 153 Sm, 177 Lu etc. have been prepared and evaluated [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . A number of such phosphonate radiopharmaceutials are in clinical use today.
Kothari et al. had earlier reported the preparation and evaluation of 186/188 Re-HEDP for bone pain palliation [32] . The same group reported synthesis, radiolabeling and evaluation of a cyclic phosphonate for bone pain palliation [68] . Starting from cyclam (1,4,8,11-tetraaza cyclotetradecane), formaldehyde and orthophosphoric acid, a tetra phosphonate ligand, 1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid or CTMP, was synthesized. This ligand was subsequently radiolabeled with Na 186 ReO 4 by heating at 100ºC for 30 min in presence of stannous chloride as reducing agent. The pH of the reaction mixture was maintained at 2. By this procedure, 186 Re-CTMP could be prepared in >97% RCP. Authors observed that 186 Re-CTMP complex remained stable at room temperature for up to 6 days post preparation. Biodistribution of 186 Re-CTMP in normal Wistar rats showed significant uptake and retention of the complex in skeleton with fast clearance from other non-target organs. A comparison with 186 Re-HEDP indicated that the pharmacokinetic parameters of 186 Re-CTMP are either similar or superior to the former [ Figure 3] . Overall, 186 Re-CTMP complex demonstrated its potential as a possible bone painpalliating agent.
2.7.4.
186/188
Re-Labeled Porphyrin for Targeted Radiotherapy
Porphyrin is a structural unit central to the oxygen transporter in our body, the hematoporphyrin. Porphyrins have shown preferential accumulation in neoplastic tissues, lymph nodes, embryonic and traumatized tissues [69] [70] [71] [72] . This property made them potential molecules for diagnosis and therapy of various diseases such as cancer [69] [70] [71] [72] [73] [74] [75] [76] [77] Tc-hematoporphyrin for in vivo imaging applications [78] . In this complex, 99m Tc was tagged at the periphery of the porphyrin ring. Thereafter, several studies were reported wherein different derivatives of porphyrins were radiolabeled with radioisotopes such 188 Re-CTMP and 188 Re-HEDP [68] . 
